STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys $1,952,611.20 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock in a transaction on Thursday, March 20th. The stock was acquired at an average cost of $17.96 per share, with a total value of $1,952,611.20. Following the acquisition, the insider now owns 12,182,995 shares in the company, valued at approximately $218,806,590.20. This represents a 0.90 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was purchased at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The stock was purchased at an average cost of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The shares were bought at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The shares were bought at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The shares were bought at an average price of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Performance

STAAR Surgical stock traded down $0.33 during mid-day trading on Thursday, reaching $17.92. 1,073,972 shares of the company were exchanged, compared to its average volume of 760,650. The business has a fifty day moving average of $19.97 and a 200 day moving average of $25.81. The firm has a market cap of $883.90 million, a P/E ratio of -43.71 and a beta of 0.66. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68.

Institutional Trading of STAAR Surgical

Hedge funds have recently bought and sold shares of the stock. Quarry LP purchased a new stake in STAAR Surgical during the third quarter worth $50,000. Quest Partners LLC purchased a new stake in shares of STAAR Surgical during the 3rd quarter valued at $128,000. KLP Kapitalforvaltning AS purchased a new stake in shares of STAAR Surgical during the 4th quarter valued at $180,000. Larson Financial Group LLC lifted its holdings in shares of STAAR Surgical by 78.3% during the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock valued at $181,000 after purchasing an additional 2,135 shares during the last quarter. Finally, Bridgefront Capital LLC lifted its holdings in shares of STAAR Surgical by 27.2% during the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on STAA shares. StockNews.com downgraded STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, February 13th. BTIG Research downgraded STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Piper Sandler decreased their target price on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 12th. William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Finally, Jefferies Financial Group cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $25.29.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.